Carisma Therapeutics Inc
NASDAQ:CARM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Czerwona Torebka SA
WSE:CZT
|
PL |
|
Changzhou Aohong Electronics Co Ltd
SSE:605058
|
CN |
|
Staidson Beijing BioPharmaceuticals Co Ltd
SZSE:300204
|
CN |
Carisma Therapeutics Inc
Other Current Liabilities
Carisma Therapeutics Inc
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Carisma Therapeutics Inc
NASDAQ:CARM
|
Other Current Liabilities
$711k
|
CAGR 3-Years
21%
|
CAGR 5-Years
12%
|
CAGR 10-Years
4%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Current Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Current Liabilities
$92m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-15%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Current Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Current Liabilities
$428.3m
|
CAGR 3-Years
11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
30%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Current Liabilities
$553m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
13%
|
|
Carisma Therapeutics Inc
Glance View
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. The company is headquartered in Cambridge, Massachusetts and currently employs 17 full-time employees. The company went IPO on 2014-02-06. The firm is focused on discovering and developing immunotherapies for patients with cancer and other serious disorders. Its platform is focused on engineered macrophages, cells that plays a role in both the innate and adaptive immune response. Its pipeline includes multiple chimeric antigen receptor (CAR) macrophages designed to target solid tumors by engineering a patient’s own immune cells. Its technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and cellular therapy for the treatment of human disease. The firm's pipeline includes CT-0508, CT-0525, CT-1119 and CT-0729. Its CT-0508 and CT-0525 is an ex vivo gene-modified autologous CAR-Macrophage cellular therapy to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2) metastasis. Its CT-1119 is a ex vivo gene-modified autologous CAR-Macrophage cellular therapy.
See Also
What is Carisma Therapeutics Inc's Other Current Liabilities?
Other Current Liabilities
711k
USD
Based on the financial report for Jun 30, 2025, Carisma Therapeutics Inc's Other Current Liabilities amounts to 711k USD.
What is Carisma Therapeutics Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
4%
Over the last year, the Other Current Liabilities growth was -63%. The average annual Other Current Liabilities growth rates for Carisma Therapeutics Inc have been 21% over the past three years , 12% over the past five years , and 4% over the past ten years .
